MedPath

Prospective, interventional study on the characterization of circulatoryTumor cells and nucleic acids in patients undergoing aLung carcinoma surgery or pulmonary metastasisctomy(Pilot study)

Not Applicable
Conditions
C34
Malignant neoplasm of bronchus and lung
Registration Number
DRKS00007565
Lead Sponsor
niversitätsklinikum Freiburg - Klinik für Thoraxchirurgie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
29
Inclusion Criteria

Group A:
- submission of written consent from the patient after informing
- Age = 18 years
Diagnosis of primary lung carcinoma or pulmonary metastases
- indication for surgical resection (atyp. Resection, lobectomy,
Pneumonectomy, metastasisctomy)
- In patients who are operated on a malignancy, the
Histopathological findings including the adequate examinations
be. No additional biopsy, examination or intervention must be within the framework
Of the study.

Group B:
-template the written consent of the patient after informing
- Age = 18 years
- Patients who have neither a history nor a suspected malignancy
(Other than basal cell carcinoma) and a lung operation due to a benign
Cause a basic disease.

Exclusion Criteria

Group A:

pregnancy
- Diagnosis of a second (synchronous) malignoma, except basal cell carcinoma.
- hemoglobin <8 g / dl on the morning of operation
- Intraoperative transfusion of more than four erythrocyte concentrates

Group B:

pregnancy
- Diagnosis of malignancy other than basal cell carcinoma.
- hemoglobin <8 g / dl on the morning of operation
- Intraoperative transfusion of more than four erythrocyte concentrates. No more
Blood collection will be taken during or on the first postoperative day.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Creation of a molecular profile of the present tumor disease using the<br>Analysis of CTCs and circulating nucleic acids in the local tumor compartment and systemically in primary and secondary lung tumors
Secondary Outcome Measures
NameTimeMethod
- Tumor recidiv<br>- Overall survival<br> - Genetic consistency of the CTCs in the local tumor compartment and systemic<br> - Comparison of different methods and removal points for the isolation of CTCs<br> -comparison cDNA, miRNA and clncRNA in the surgical preparation with the circulating RNAs systemically as well as from the immediate tumor discharge<br>- Expression of driver mutations of the CTCs
© Copyright 2025. All Rights Reserved by MedPath